Medical technology giant Becton Dickinson & Co. announced Thursday it has reached a settlement of $22 million to end four class action lawsuits against the firm accusing the company of attempting to monopolize the hypodermic needle market. Specifically, members of the class action claimed BD of squeezing competitors out of the market by offering steep discounts on bundled hospital equipment products so long as hospitals agreed to buy the majority of their needles from BD. Further, BD was accused of giving company stock to group purchasing organizations, which determine prices set for hospitals. Court documents allege that such agreements were anticompetitive, violated antitrust law, raised prices and reduced innovation. The company announced the settlement along with its third-quarter earnings report. BD says the settlement cut share prices by 7 cents.
Featured News
Realtors Group to Pay $52 Million to Settle Homebuyer Antitrust Claims
Apr 10, 2026 by
CPI
Delaware Wants to be the Regulatory Home for Stablecoins
Apr 10, 2026 by
CPI
Bessent, Powell Summon Bank CEOs Over Anthropic’s New AI Model
Apr 10, 2026 by
CPI
Florida Attorney General Launches Investigation Into OpenAI and ChatGPT
Apr 9, 2026 by
CPI
Chainalysis Sees Stablecoins Becoming Core Global Payment Infrastructure
Apr 9, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Competitor Collaborations
Mar 26, 2026 by
CPI
Between Scylla and Charybdis – Navigating Transatlantic Antitrust Currents
Mar 26, 2026 by
Tilman Kuhn & Niklas Brüggemann
Cartel Enforcement Moves Into the Labor Market: Trends and Implications
Mar 26, 2026 by
Andreas Kafetzopoulos & Caroline Janssens
Rethinking Buy-Side Antitrust “Group Boycotts”
Mar 26, 2026 by
Craig Falls & Brendan McGuire
Positive Collaborations: The Tools Available to Competition Authorities to Encourage Beneficial Interactions Between Competitors
Mar 26, 2026 by
Rona Bar-Isaac & Thomas Withers